Carregant...

RING domain–deficient BRCA1 promotes PARP inhibitor and platinum resistance

Patients with cancers that harbor breast cancer 1 (BRCA1) mutations initially respond well to platinum and poly(ADP-ribose) polymerase inhibitor (PARPi) therapy; however, resistance invariably arises in these patients and is a major clinical problem. The BRCA1(185delAG) allele is a common inherited...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Invest
Autors principals: Wang, Yifan, Krais, John J., Bernhardy, Andrea J., Nicolas, Emmanuelle, Cai, Kathy Q., Harrell, Maria I., Kim, Hyoung H., George, Erin, Swisher, Elizabeth M., Simpkins, Fiona, Johnson, Neil
Format: Artigo
Idioma:Inglês
Publicat: American Society for Clinical Investigation 2016
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4966309/
https://ncbi.nlm.nih.gov/pubmed/27454289
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI87033
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!